LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced results from preclinical studies evaluating the treatment effect of a research form of KER-065 (“RKER-065”) in a mouse model of Duchenne muscular dystrophy (“DMD”) and in prednisolone-treated mice, which were presented at the 28th International Annual Congress of the World Muscle Society (“WMS”) on Wednesday, October 4, 2023.

2023年10月4日（GLOBE NEWSWIRE）-Keros Therapeutics，Inc.（“Keros”）（纳斯达克股票代码：KROS），一家临床阶段的生物制药公司，专注于开发和商业化新型治疗药物，以治疗广泛的与转化生长因子β（“TGF-β”）蛋白家族功能失调信号传导有关的疾病患者，今天公布了2023年10月4日星期三在杜兴氏肌营养不良症（“DMD”）小鼠模型和泼尼松龙治疗小鼠中评估研究形式KER-065（“RKER-065”）治疗效果的临床前研究结果。第28届世界肌肉学会国际年会（“WMS”）。

“We are pleased to present promising preclinical data from our KER-065 program at WMS this year, showing that treatment with RKER-065 led to a robust increase in muscle mass, muscle function and bone mass in a mouse model of DMD and in prednisolone-treated mice,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros.

“我们很高兴今年在WMS的KER-065计划中提供有希望的临床前数据，表明用RKER-065治疗导致DMD小鼠模型和泼尼松龙治疗小鼠的肌肉质量，肌肉功能和骨量显着增加，”Keros总裁兼首席执行官Jasbir S.Seehra博士说。

“We believe these data support the potential of KER-065 to treat multiple pathophysiologies of DMD and other neuromuscular diseases, and we look forward to commencing a Phase 1 clinical trial of KER-065 in healthy volunteers in the first quarter of 2024.” RKER-065 treatment led to a robust increase in muscle mass, functional strength, and bone formation in a DMD mouse model RKER-065 ameliorated muscle and bone loss in a progressive murine model of Duchenne muscular dystrophy Keros studied the effect of RKER-065 in a progressive and phenotypically severe DMD mouse model.

“我们相信这些数据支持KER-065治疗DMD和其他神经肌肉疾病的多种病理生理学的潜力，我们期待在2024年第一季度在健康志愿者中开始KER-065的第一阶段临床试验。”RKER-065治疗导致肌肉质量，功能强度，DMD小鼠模型中的骨形成RKER-065改善了Duchenne肌营养不良症的进行性小鼠模型中的肌肉和骨丢失Keros研究了RKER-065在进行性和表型严重DMD小鼠模型中的作用。

DMD mice were dosed with vehicle or 10 mg/kg of RKER-065 once weekly for four or six weeks. A cohort of healthy mice received only vehicle. In DMD mice, treatment with.

DMD小鼠每周一次给予载体或10mg/kg RKER-065，持续4或6周。一组健康小鼠仅接受载体。在DMD小鼠中，用。